Drugs /

mcla-158

Back to Drugs List

Overview

NCI Definition [1]:
An immunoglobulin G1 (IgG1) bispecific antibody targeting both epidermal growth factor receptor (EGFR; HER1; ErbB1) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, anti-EGFR/LGR5 bispecific antibody MCLA-158 simultaneously targets and binds to both EGFR and LGR5, thereby inhibiting the activation of both EGFR- and LGR5-mediated signaling pathways. This results in the inhibition of tumor cell proliferation. EGFR, a receptor tyrosine kinase (RTK) upregulated and/or mutated in a variety of tumor cell types, plays an important role in tumor cell proliferation. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.

Clinical Trials

View Clinical Trials for mcla-158

Mcla-158 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mcla-158, 1 is phase 1 (1 open).

Colorectal carcinoma and malignant solid tumor are the most common diseases being investigated in mcla-158 clinical trials [2].

Drug Details

Synonyms [2]:
bispecific antibody mcla-158, mcla 158, anti-egfr/anti-lgr5 bispecific antibody mcla-158, anti-egfr/lgr5 bispecific antibody mcla-158, egfr x lgr5 bispecific antibody mcla-158
Drug Target(s) [2]:
EGFR, LGR5
NCIT ID [1]:
C179196

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.